Sphingosine 1-phosphate receptor subtype 1 (S1P1) activity in the course of Alzheimer's disease

Some specific lipid molecules in the brain act as signaling molecules, neurotransmitters, or neuromodulators, by binding to specific G protein-coupled receptors (GPCR) for neurolipids. One such receptor, sphingosine 1-phosphate receptor subtype 1 (S1P<sub>1</sub>), is coupled to G<sub>i/o</sub> proteins and is involved in cell proliferation, growth, and neuroprotection. S1P<sub>1</sub> constitutes an interesting target for neurodegenerative diseases like multiple sclerosis and Alzheimer's disease (AD), in which changes in the sphingolipid metabolism have been observed. This study analyzes S1P<sub>1</sub> receptor-mediated activity in healthy brains and during AD progression using postmortem samples from controls and patients at different Braak's stages. Additionally, the distribution of S1P<sub>1</sub> receptor activity in human brains is compared to that in commonly used rodent models, rats and mice, through functional autoradiography, measuring [<sup>35</sup>S]GTPγS binding stimulated by the S1P<sub>1</sub> receptor selective agonist CYM-5442 to obtain the distribution of functional activity of S1P<sub>1</sub> receptors. S1P<sub>1</sub> receptor-mediated activity, along with that of the cannabinoid CB<sub>1</sub> receptor, is one of the highest recorded for any GPCR in many gray matter areas of the brain, reaching maximum values in the cerebellar cortex, specific areas of the hippocampus and the basal forebrain. S1P<sub>1</sub> signaling is crucial in areas that regulate learning, memory, motor control, and nociception, such as the basal forebrain and basal ganglia. In AD, S1P<sub>1</sub> receptor activity is increased in the inner layers of the frontal cortex and underlying cortical white matter at early stages, but decreases in the hippocampus in advanced stages, indicating ongoing brain impairment. Importantly, we identified significant correlations between S1P<sub>1</sub> receptor activity and Braak stages, suggesting that S1P<sub>1</sub> receptor dysfunction is associated to disease progression, particularly in memory-related regions. The S1P signaling via S1P<sub>1</sub> receptor is a promising neurological target due to its role in key neurophysiological functions and its potential to modify the progression of neurodegenerative diseases. Finally, rats are suggested as a preferred experimental model for studying S1P<sub>1</sub> receptor-mediated responses in the human brain.

Authors

Institutions

Publication Details

Journal
Neurobiology of Disease
Published
2024-10-22
DOI
https://doi.org/10.1016/j.nbd.2024.106713
Citations
5
Primary Topic
Sphingolipid Metabolism and Signaling
Type
article
Field-Weighted Citation Impact
1.17

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Sphingosine 1-phosphate receptor subtype 1 (S1P1) activity in the course of Alzheimer's disease

Gorka Pereira‐Castelo, Ivan Fernández‐Vega, Jonatan Martínez‐Gardeazabal, Alberto Llorente‐Ovejero et al.
5 citations
Neurobiology of Disease
Sphingolipid Metabolism and Signaling
1.17
article

Sphingosine 1-phosphate receptor subtype 1 (S1P1) activity in the course of Alzheimer's disease

Gorka Pereira‐Castelo, Ivan Fernández‐Vega, Jonatan Martínez‐Gardeazabal, Alberto Llorente‐Ovejero, Marta Moreno‐Rodríguez, Rafael Rodríguez‐Puertas, Iván Manuel, Manuel Fernández
article en
5 citations

Abstract

Some specific lipid molecules in the brain act as signaling molecules, neurotransmitters, or neuromodulators, by binding to specific G protein-coupled receptors (GPCR) for neurolipids. One such receptor, sphingosine 1-phosphate receptor subtype 1 (S1P<sub>1</sub>), is coupled to G<sub>i/o</sub> proteins and is involved in cell proliferation, growth, and neuroprotection. S1P<sub>1</sub> constitutes an interesting target for neurodegenerative diseases like multiple sclerosis and Alzheimer's disease (AD), in which changes in the sphingolipid metabolism have been observed. This study analyzes S1P<sub>1</sub> receptor-mediated activity in healthy brains and during AD progression using postmortem samples from controls and patients at different Braak's stages. Additionally, the distribution of S1P<sub>1</sub> receptor activity in human brains is compared to that in commonly used rodent models, rats and mice, through functional autoradiography, measuring [<sup>35</sup>S]GTPγS binding stimulated by the S1P<sub>1</sub> receptor selective agonist CYM-5442 to obtain the distribution of functional activity of S1P<sub>1</sub> receptors. S1P<sub>1</sub> receptor-mediated activity, along with that of the cannabinoid CB<sub>1</sub> receptor, is one of the highest recorded for any GPCR in many gray matter areas of the brain, reaching maximum values in the cerebellar cortex, specific areas of the hippocampus and the basal forebrain. S1P<sub>1</sub> signaling is crucial in areas that regulate learning, memory, motor control, and nociception, such as the basal forebrain and basal ganglia. In AD, S1P<sub>1</sub> receptor activity is increased in the inner layers of the frontal cortex and underlying cortical white matter at early stages, but decreases in the hippocampus in advanced stages, indicating ongoing brain impairment. Importantly, we identified significant correlations between S1P<sub>1</sub> receptor activity and Braak stages, suggesting that S1P<sub>1</sub> receptor dysfunction is associated to disease progression, particularly in memory-related regions. The S1P signaling via S1P<sub>1</sub> receptor is a promising neurological target due to its role in key neurophysiological functions and its potential to modify the progression of neurodegenerative diseases. Finally, rats are suggested as a preferred experimental model for studying S1P<sub>1</sub> receptor-mediated responses in the human brain.

Neurobiology of DiseaseVol. 202
University of the Basque Country (ES)
Hezkuntza, Hizkuntza Politika Eta Kultura Saila, Eusko Jaurlaritza, European Commission, Eusko Jaurlaritza, Ministerio de Economía y Competitividad, Euskal Herriko Unibertsitatea, Instituto de Salud Carlos III, European Regional Development Fund, Berrikuntza + Ikerketa + Osasuna Eusko Fundazioa, European Social Fund
Openalex Percentile: Top 21%
Sphingolipid Metabolism and Signaling
1.17
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.